Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Abcam Introduces Exclusive Range of Highly Validated Antibody Conjugates

Published: Wednesday, September 03, 2014
Last Updated: Wednesday, September 03, 2014
Bookmark and Share
Offering reliable and specific research tools for multi-color experiments.

Abcam plc has announced that it has launched an exclusive range of highly validated conjugated antibodies for use in key imaging applications including immunofluorescence, flow cytometry, and fluorescent western blotting.

Abcam’s conjugated antibodies enable scientists to easily perform multi-protein analysis. It is essential for scientists to study and image proteins in their multi-component state rather than individually, as research findings indicate that proteins rarely operate in isolation but function within multi-protein complexes.

The majority of the new antibodies are developed using Abcam’s RabMAb® technology, and are conjugated to Alexa Fluor® dyes, HRP, or biotin, combining high signal to noise ratios with high specificity. Each antibody has been produced and extensively validated by Abcam’s scientists. Performance data including images, references and customer reviews is provided with each product.

Matthew Roe, Head of Reagents, Abcam, commented: “Product quality is of critical importance to Abcam. We’re developing our in-house product ranges, focusing on high production standards and verifying quality though additional in-house and independent validation.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Abcam Acquires AxioMx
AxioMx provides a unique, cost-effective, and proprietary platform to produce recombinant monoclonal antibodies complementing Abcam's existing innovative production capabilities.
Friday, November 13, 2015
Abcam Acquires Firefly BioWorks
Acquisition will expand Abcam’s capabilities in multiplex analysis.
Wednesday, January 21, 2015
Abcam Partners with A*STAR’s Institute of Molecular and Cell Biology
Abcam Partners with A*STAR’s Institute of Molecular and Cell Biology.
Thursday, January 08, 2015
Abcam plc Announces Board Appointment
Appointment of Sue Harris as a non-Executive Director on the Company’s Board.
Saturday, December 13, 2014
Abcam Appoints Yvonne Chien as Chief Digital Officer
Abcam’s leadership team strengthened by new appointments.
Saturday, December 13, 2014
Abcam Wins ‘Best Use of Digital Media’ at Life Science Industry Awards
Awards recognise the world’s top performing life science suppliers.
Wednesday, November 19, 2014
Abcam Licenses Multidrug Resistance Protein 4 Inhibitors
Compounds allow further exploration of MRP4 function and have potential in cancer therapeutic development.
Tuesday, September 23, 2014
Abcam and Cell Marque Sign Global Strategic Marketing Agreement
Partnership extends Abcam’s reach within in vitro diagnostics market.
Saturday, September 06, 2014
Abcam Establishes New Direct Service for Australia and New Zealand
New service will offer researchers improved delivery times and direct technical support.
Tuesday, August 12, 2014
Abcam Announces Winner of 15 Discoveries Contest
Contest celebrates scientific breakthroughs with $15,000 research grant.
Tuesday, February 04, 2014
Abcam to Open Office in Shanghai
New office will provide dedicated support to Chinese customers.
Tuesday, January 21, 2014
Abcam Named AIM Company of the Year
The AIM awards celebrate outstanding achievement of quoted companies and entrepreneurs who have harnessed AIM to help them fulfil their ambition and growth potential in the last twelve months.
Monday, October 14, 2013
Abcam Appoints Alan Hirzel as Chief Marketing Officer
New role will support future growth strategies at Abcam.
Friday, June 28, 2013
Abcam Signs License Agreement with Pfizer
Company to supply a range of authentic Pfizer compounds to researchers.
Wednesday, June 12, 2013
Abcam Licenses Novel Technology from Columbia University for Neurobiological Research
New products from Abcam Biochemicals will support research into neurodegeneration and drug addiction.
Monday, April 08, 2013
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Promising Drug Combination for Advanced Prostate Cancer
A new drug combination may be effective in treating men with metastatic prostate cancer. Preliminary results of this new approach are encouraging and have led to an ongoing international study being conducted in 196 hospitals worldwide.
A Cellular Symphony Responsible for Autoimmune Disease
Broad Institute researchers have used a novel approach to increase our understanding of the immune system as a whole.
When it Comes to Breast Cancer, Common Pigeon is No Bird Brain
If pigeons went to medical school and specialized in pathology or radiology, they’d be pretty good at distinguishing digitized microscope slides and mammograms of normal vs. cancerous breast tissue, a new study has found.
Editing of LIMS Data Made Faster and More Efficient in Matrix Gemini
The latest version of the Matrix Gemini LIMS (Laboratory Information Management System) from Autoscribe Informatics now provides faster and more efficient editing of LIMS data by eliminating the need for a second editing screen.
How a Genetic Locus Protects Adult Blood-Forming Stem Cells
Mammalian imprinted Gtl2 protects adult hematopoietic stem cells by restricting metabolic activity in the cells' mitochondria.
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
The MaxSignal Colistin ELISA Test Kit from Bioo Scientific
Kit can help prevent the antibiotic apocalypse by keeping last resort drugs out of the food supply.
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos